Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients | Zendy

Diwakar Davar | Zendy; Amiran Dzutsev | Zendy; John A. McCulloch | Zendy; Richard R. Rodrigues | Zendy; Joë-Marc Chauvin | Zendy; Robert M. Morrison | Zendy; Richelle DeBlasio | Zendy; Carmine Menna | Zendy; Quanquan Ding | Zendy; Ornella Pagliano | Zendy; Bochra Zidi | Zendy; Shuowen Zhang | Zendy; Jonathan H. Badger | Zendy; Marie Vétizou | Zendy; Alicia M. Cole | Zendy; Miriam R. Fernandes | Zendy; Stephanie Prescott | Zendy; Raquel Costa | Zendy; Ascharya K. Balaji | Zendy; Andrey Morgun | Zendy; Ivan Vujkovic-Cvijin | Zendy; Hong Wang | Zendy; Amir A. Borhani | Zendy; Marc Schwartz | Zendy; Howard M. Dubner | Zendy; S. Ernst | Zendy; Amy Rose | Zendy; Yana G. Najjar | Zendy; Yasmine Belkaid | Zendy; John M. Kirkwood | Zendy; Giorgio Trinchieri | Zendy; Hassane M. Zarour | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Author(s) -

Diwakar Davar,

Amiran Dzutsev,

John A. McCulloch,

Richard R. Rodrigues,

Joë-Marc Chauvin,

Robert M. Morrison,

Richelle DeBlasio,

Carmine Menna,

Quanquan Ding,

Ornella Pagliano,

Bochra Zidi,

Shuowen Zhang,

Jonathan H. Badger,

Marie Vétizou,

Alicia M. Cole,

Miriam R. Fernandes,

Stephanie Prescott,

Raquel Costa,

Ascharya K. Balaji,

Andrey Morgun,

Ivan Vujkovic-Cvijin,

Hong Wang,

Amir A. Borhani,

Marc Schwartz,

Howard M. Dubner,

S. Ernst,

Amy Rose,

Yana G. Najjar,

Yasmine Belkaid,

John M. Kirkwood,

Giorgio Trinchieri,

Hassane M. Zarour

Publication year - 2021

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.abf3363

Subject(s) - fecal bacteriotherapy , feces , resistance (ecology) , melanoma , microbiology and biotechnology , medicine , biology , immunology , cancer research , ecology , clostridium difficile , antibiotics

New fecal microbiota for cancer patients The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruchet al. and Davaret al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8+ T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients.Science , this issue p.602 , p.595 ; see also p.573

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research